YOUZAN(06051) 2026 Spring Conference: AI enters the efficacy verification stage
Youzan's Spring 2026 release conference will be held in Hangzhou on May 21st, with the theme "Effective AI".
YOUZAN's 2026 spring launch event was held in Hangzhou on May 21st, with the theme of "Effective AI". Over the past year, YOUZAN's intelligent system and digital employees have entered a new stage of delivering results. Data shows that in 2025, the YOUZAN AI intelligent system was actively used by 18,220 merchants, with a total call volume of over 36 million times, leading to a turnover of over 241 million yuan. The AI digital employee has served 877,000 customers and completed 6.13 million conversations in six months, generating over 557 million yuan in sales. The AI marketing expert has cumulatively generated nearly 3 billion yuan in sales in six months, effectively helping merchants sell more, acquire more customers, and earn more money.
In the era of AI, what merchants need is the ability to "truly deliver results". From intelligent systems, digital employees to "add me as a recommendation officer", YOUZAN is helping merchants embed AI into the entire chain of customer acquisition, conversion, and repurchase, making every content production, customer reach, and business decision more efficient, certain, and effective.
Related Articles

Build a strong line of defense against risks, safeguard financial security. CBHB (09668) held a large-scale competition on operational skills covering nearly 8000 participants.

Apeloa Pharmaceutical (000739.SZ): The addition of a new 25mg specification for Metoprolol Succinate Extended-Release Tablets has been approved by the US FDA.

Shanghai Shyndec Pharmaceutical (600420.SH): Ibrutinib Capsules Obtain Drug Registration Certificate.
Build a strong line of defense against risks, safeguard financial security. CBHB (09668) held a large-scale competition on operational skills covering nearly 8000 participants.

Apeloa Pharmaceutical (000739.SZ): The addition of a new 25mg specification for Metoprolol Succinate Extended-Release Tablets has been approved by the US FDA.

Shanghai Shyndec Pharmaceutical (600420.SH): Ibrutinib Capsules Obtain Drug Registration Certificate.






